Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1979 1
1980 1
1981 1
1982 4
1983 1
1984 3
1985 1
1994 1
1995 1
1996 1
1998 1
1999 1
2001 1
2003 1
2004 4
2005 3
2006 9
2007 6
2008 4
2009 5
2010 4
2011 6
2012 10
2013 6
2014 5
2015 2
2016 2
2017 2
2018 2
2019 1
2020 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

83 results
Results by year
Filters applied: . Clear all
Page 1
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Loibl S, Turner NC, Ro J, Cristofanilli M, Iwata H, Im SA, Masuda N, Loi S, André F, Harbeck N, Verma S, Folkerd E, Puyana Theall K, Hoffman J, Zhang K, Bartlett CH, Dowsett M. Loibl S, et al. Among authors: folkerd e. Oncologist. 2017 Sep;22(9):1028-1038. doi: 10.1634/theoncologist.2017-0072. Epub 2017 Jun 26. Oncologist. 2017. PMID: 28652278 Free PMC article. Clinical Trial.
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.
Johnston SR, Kilburn LS, Ellis P, Dodwell D, Cameron D, Hayward L, Im YH, Braybrooke JP, Brunt AM, Cheung KL, Jyothirmayi R, Robinson A, Wardley AM, Wheatley D, Howell A, Coombes G, Sergenson N, Sin HJ, Folkerd E, Dowsett M, Bliss JM; SoFEA investigators. Johnston SR, et al. Among authors: folkerd e. Lancet Oncol. 2013 Sep;14(10):989-98. doi: 10.1016/S1470-2045(13)70322-X. Epub 2013 Jul 29. Lancet Oncol. 2013. PMID: 23902874 Free article. Clinical Trial.
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS. Attard G, et al. Among authors: folkerd e. J Clin Oncol. 2008 Oct 1;26(28):4563-71. doi: 10.1200/JCO.2007.15.9749. Epub 2008 Jul 21. J Clin Oncol. 2008. PMID: 18645193 Clinical Trial.
Menstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancer.
Haynes BP, Ginsburg O, Gao Q, Folkerd E, Afentakis M, Buus R, Quang LH, Thi Han P, Khoa PH, Dinh NV, To TV, Clemons M, Holcombe C, Osborne C, Evans A, Skene A, Sibbering M, Rogers C, Laws S, Noor L, Smith IE, Dowsett M. Haynes BP, et al. Among authors: folkerd e. NPJ Breast Cancer. 2019 Nov 15;5:42. doi: 10.1038/s41523-019-0138-2. eCollection 2019. NPJ Breast Cancer. 2019. PMID: 31754627 Free PMC article.
Influence of sex hormones on cancer progression.
Folkerd EJ, Dowsett M. Folkerd EJ, et al. J Clin Oncol. 2010 Sep 10;28(26):4038-44. doi: 10.1200/JCO.2009.27.4290. Epub 2010 Jul 19. J Clin Oncol. 2010. PMID: 20644089 Review.
83 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page